Moleculin Biotech
MBRX
17 hedge funds and large institutions have $315K invested in Moleculin Biotech in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 12 closing their positions.
3.03% more ownership
Funds ownership: 0.06% → 3.09% (+3%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
24% less capital invested
Capital invested by funds: $413K → $315K (-$97.5K)
29% less funds holding
Funds holding: 24 → 17 (-7)
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$308K |
| 2 |
Jane Street
New York
|
+$210K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$63.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$53.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$61K |
| 2 |
LPL Financial
San Diego,
California
|
-$30.8K |
| 3 |
IC
IEQ Capital
Foster City,
California
|
-$19.3K |
| 4 |
WDG
Wealth Dimensions Group
Cincinnati,
Ohio
|
-$10.6K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$7K |
MBRX Hedge Fund Activity: Q4 2025 in Review
17 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2025, worth a combined $315K — down 24% from $413K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of MBRX and 5 opened new positions — a net loss of 7 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $308K. The largest seller was HRT Financial, exiting entirely with an estimated $61K sold.
- 17 institutional investors held Moleculin Biotech (MBRX) as of Q4 2025, down from 24 in Q3 2025.
- Funds reported $315K of Moleculin Biotech stock for Q4 2025, down 24% quarter-over-quarter.
- 5 funds opened new Moleculin Biotech positions in Q4 2025 and 12 closed out, a net change of -7 holders.
- The largest Moleculin Biotech buyer in Q4 2025 was Citadel Advisors, an estimated $308K added.
- The largest Moleculin Biotech seller in Q4 2025 was HRT Financial, an estimated $61K sold.
Based on aggregated 13F filings for Q4 2025.